What's new? Log in Free sign up

IMV (IMV) News and press releases

Company Profile

News

From Benzinga Pro

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

HC Wainwright & Co. Downgrades IMV to Neutral

News, Downgrades, Analyst Ratings

HC Wainwright & Co. analyst Joseph Pantginis downgrades IMV (NASDAQ:IMV) from Buy to Neutral.

IMV Initiates Restructuring Proceedings Under The CCAA To Complete The Review Of Its Strategic Alternatives

News, Management

IMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and

Why Bed Bath & Beyond Shares Are Trading Lower By 23%; Here Are 20 Stocks Moving Premarket

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

IMV Inc. ("IMV" or the "Company") (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and

HC Wainwright & Co. Reiterates Buy on IMV - 1-for-10 reverse stock

News, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Joseph Pantginis reiterates IMV (NASDAQ:IMV) with a Buy, 1-for-10 reverse stock

Earnings Scheduled For March 15, 2023

Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million.

IMV's Earnings: A Preview

Press releases

From Benzinga Pro

IMV Receives NASDAQ Delisting Notice

IMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and

Horizon Technology Finance Announces First Quarter 2023 Financial Results

Earnings, Commodities, Press Releases

- First Quarter 2023 Net Investment Income per Share of $0.46; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to $715 Million - - Horizon Platform Ends Quarter with

IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives

IMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and

IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

IMV Inc. ("IMV" or the "Company") (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today

IMV Inc. Announces Changes to Its Board of Directors

IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced changes to its

IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results

Advanced lead candidate, MVP-S, in two global Phase 2B clinical trials and enhanced the scientific differentiation of the DPX platform Observed multiple complete clinical responses in relapsed/refractory DLBCL and

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.